Colhoun HM, Leiter LA, Müller-Wieland D, et al. - Given that the influences of alirocumab on people with non-HDL-C ≥ 100 mg/dL and triglycerides (TGs) ≥ 150 and < 500 mg/dL taking stable maximally tolerated statin (n = 413) has been shown by the earlier reported open-label ODYSSEY DM-DYSLIPIDEMIA trial data, researchers undertook this post hoc subgroup study of the primary trial to determine how alirocumab [75 mg every 2 weeks (Q2W) with possible rise to 150 mg Q2W at Week 12] vs usual care [ezetimibe, fenofibrate, or no additional lipid-lowering therapy (LLT)] influences non-HDL-C as well as other lipids in people with T2D and baseline TGs ≥ 200 mg/dL and HDL-C < 40 mg/dL (men) or < 50 mg/dL (women). A significant decrease in non-HDL-C, apolipoprotein B (ApoB), LDL-C, LDL particle number, and lipoprotein (a) was achieved with alirocumab vs usual care from baseline to Week 24. Findings revealed the effectiveness of alirocumab as a treatment choice for people with T2D, TGs ≥ 200 mg/dL, and HDL-C < 40 mg/dL (men) or < 50 mg/dL (women). Greater decreases in atherogenic lipid (ApoB and non-HDL) was achieved with alirocumab vs ezetimibe, fenofibrate, or no LLT. Consistent with prior investigations, the general good tolerability of alirocumab was reported in this study.